Deep Learning (DL) can predict biomarkers from cancer histopathology. Several clinically
approved applications use this technology. Most approaches, however, predict categorical …

Background Clinical benefits of atezolizumab plus bevacizumab (atezolizumab–bevacizumab)
are observed only in a subset of patients with hepatocellular carcinoma and the …

Medical image classification requires labeled, task-specific datasets which are used to train
deep learning networks de novo, or to fine-tune foundation models. However, this process is …

Multimodal artificial intelligence (AI) systems have the potential to enhance clinical decision-making
by interpreting various types of medical data. However, the effectiveness of these …

Hematoxylin- and eosin (H&E) stained whole-slide images (WSIs) are the foundation of
diagnosis of cancer. In recent years, development of deep learning-based methods in …

The weakly supervised DL model to predict PD-L1 status from raw IHC data, integrating
tumor staining intensity and morphology, enables enhanced patient stratification in cancer …

Background Deep Learning (DL) can predict molecular alterations of solid tumors directly
from routine histopathology slides. Since the 2021 update of the World Health Organization (…

Deep learning is revolutionising pathology, offering novel opportunities in disease
prognosis and personalised treatment. Historically, stain normalisation has been a crucial …

Deep Learning (DL) can predict biomarkers directly from digitized cancer histology in a
weakly-supervised setting. Recently, the prediction of continuous biomarkers through regression-…

Deep Learning models have been successfully utilized to extract clinically actionable
insights from routinely available histology data. Generally, these models require annotations …